StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Research analysts at StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

NASDAQ:BLPH opened at $0.01 on Monday. The firm’s fifty day moving average price is $0.02 and its two-hundred day moving average price is $0.03. The company has a market cap of $146,796.00, a P/E ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a one year low of $0.01 and a one year high of $0.02.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.